Isabelle Soerjomataram’s research while affiliated with International Agency for Research on Cancer and other places

What is this page?


This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.

Publications (314)


Stat Bite: Infectious agents as global causes of cancer in 2020
  • Article

June 2025

JNCI Journal of the National Cancer Institute

Isabelle Soerjomataram

·

Freddie Bray

Cutaneous melanoma attributable to ultraviolet radiation (UVR) globally for people aged 30–99 by world region in 2022 for (A) both sexes, (B) males, and (C) females. The percentage of attributable cases for each region out of total attributable cases for a given sex can also be seen. [Color figure can be viewed at wileyonlinelibrary.com]
Estimated (A) population attributable fraction (PAF) (%) of cutaneous melanoma related to ultraviolet radiation (UVR) and (B) age‐standardized rates (ASR) of CM cases attributable to UVR, per 100,000 people in 2022, by country. In case of small incidence rates, a moderate PAF can translate into a very small attributable ASR. [Color figure can be viewed at wileyonlinelibrary.com]
The 15 countries with the highest attributable age‐standardized rates (ASR) of cutaneous melanoma associated with Ultraviolet radiation by sex in 2022. [Color figure can be viewed at wileyonlinelibrary.com]
Sensitivity analysis using the regional and Thames reference alongside the main analysis results using the NORDCAN reference for (A) the population attributable fraction and (B) attributable age‐standardized rate (ASR), by world region. Uncertainty intervals are indicated by colored lines. [Color figure can be viewed at wileyonlinelibrary.com]
Global burden of cutaneous melanoma incidence attributable to ultraviolet radiation in 2022
  • Article
  • Publisher preview available

May 2025

·

16 Reads

·

·

Esther de Vries

·

[...]

·

Isabelle Soerjomataram

Cutaneous melanoma (CM) accounted for around 331,700 cancer cases globally in 2022. Ultraviolet radiation (UVR) is a major CM risk factor. In this study, we update and improve global estimates of UVR‐attributable CM cases. Population attributable fractions (PAFs) were calculated by age, sex, and country using GLOBOCAN 2022 national incidence estimates comparing to a minimally exposed Nordic 1930 birth cohort reference population. Adjustments for acral lentiginous melanoma were made to exclude non‐UVR‐associated melanomas. In sensitivity analyses, PAFs were recalculated with a theoretical minimally exposed 1903 South Thames, England birth cohort and world region‐specific reference populations. An estimated 267,353 (95% uncertainty intervals [UI]: 242,818, 278,638) CM cases were UVR attributable globally in 2022. Males contributed to a larger proportion (57%, 151,921 out of 267,353) of UVR‐attributable CMs. We found significant regional variation with the highest PAF observed in Australia/ New Zealand, Northern Europe, and North America, all with more than 95% CM cases UVR‐attributable. Attributable age‐standardized rates were highest in regions with populations of lighter skin color such as Australia/New Zealand, Northern Europe, and North America, with 75.68 (95%UI: 74.50, 76.86), 36.82 (95%UI: 36.38, 37.26) and 33.69 (95%UI: 33.47, 33.91) attributable cases per 100,000 people. By age group, the burden increased with age, with PAF of 76.39% (95%UI: 66.24, 81.01) among people aged 30–49 versus 86.13% (95%UI: 80.04, 88.99) among 70+ years. Most of the global CM burden in 2022 was UVR‐attributable. Primary prevention through increasing sun safety awareness and affordable sun protection provision options is key to reducing CM.

View access options







Map of the global burden of female breast cancer in 2022
Estimated age-standardized rates of incidence (a) and mortality (b) for female breast cancer per 100,000 in 2022, for 185 countries. Reproduced from ref. ³⁶. Copyright 2025 IARC/WHO.
Global disparities in female breast cancer incidence and mortality, by Human Development Index (HDI)
Estimated age-standardized rates of incidence and mortality for female breast cancer per 100,000 in 2022 (left) and M:I ratio (right), by HDI level.
Cumulative lifetime risk of female breast cancer, by continent
Estimated cumulative risk of developing (a) or dying from (b) female breast cancer (%) before the age of 75 years, by continent, with corresponding minimum and maximum cumulative risks within continents.
Ten-year trends in female breast cancer incidence and mortality
Ten-year estimated annual percentage change in rates of incidence (a) and mortality (b) of female breast cancer, in 2008–2017 unless otherwise specified (a2007–2016; b2006–2015), overall and by age at diagnosis (<50 years, 50+ years).
Future burden of female breast cancer in 2050
Projected incidence (a) and mortality (b) of new breast cancer cases in 2050 (percentage increase from 2022) based on HDI levels.
Global patterns and trends in breast cancer incidence and mortality across 185 countries

February 2025

·

547 Reads

·

55 Citations

Nature Medicine

Updates of current and projected estimates of the burden are critical to monitoring the success of ongoing efforts in breast cancer control, such as the World Health Organization Global Breast Cancer Initiative, which aims to reduce breast cancer mortality by 2.5% per year. We investigated the current (2022) and future (2050) global burden of female breast cancer overall, and by age group, in 185 countries using the GLOBOCAN database, and 10-year trends in incidence and mortality rates in 50 and 46 countries, respectively, using the Cancer Incidence in Five Continents plus and World Health Organization mortality databases. Globally, 2.3 million new cases and 670,000 deaths from female breast cancer occurred in 2022. Annual rates increased by 1–5% in half of examined countries. Mortality rates decreased in 29 countries with very high Human Development Index (HDI), and seven countries (for example, Belgium and Denmark) are meeting the Global Breast Cancer Initiative goal of at least a 2.5% decrease each year. By 2050, new cases and deaths will have increased by 38% and 68%, respectively, disproportionately impacting low-HDI countries. High-quality cancer and vital status data, and continued progress in early diagnosis and access to treatment, are needed in countries with low and medium HDI to address inequities and monitor cancer control goals.



Citations (71)


... The Global Burden of Disease Study indicated a notable increase in pancreatic cancer cases and deaths from 1990 to 2017, especially in high-income areas [111]. In Southeast Asia, both the incidence and mortality of this type of cancer are increasing and are projected to significantly increase by 2050 [112]. The initiation of abnormally activated lipid metabolic reprogramming plays a key role in the development of PDAC, which can develop into a deadly malignant tumour with a high probability of recurrence and distant metastasis [69]. ...

Reference:

Unlocking the lipid code: SREBPs as key drivers in gastrointestinal tumour metabolism
Cancer incidence and mortality estimates in 2022 in southeast Asia: a comparative analysis
  • Citing Article
  • February 2025

The Lancet Oncology

... Breast cancer (BC), one of the leading causes of death for women worldwide, has drawn attention as a significant issue for women's health [1]. This tumor was the most prevalent neoplasm worldwide, surpassing lung cancer in frequency, according to data from the GLOBOCAN survey and 3.2 million new cases of BC and 1.1 million annual deaths from the disease are predicted by 2050 [2,3]. Thus, screening and preventative initiatives are the most effective means of reducing the incidence and mortality of BC [4]. ...

Global patterns and trends in breast cancer incidence and mortality across 185 countries

Nature Medicine

... Literature shows high-income countries (HICs) having higher survival rates, in contrast to those reported by LMICs [7,8]. This is linked to system challenges such as limited resources for early detection, optimal cytoreductive surgery and drug treatment, surveillance in LMICs [9,10], and patient challenges such as delayed presentation [11]. Therefore, proactive strategies, including increased resource allocation and improved access to training, diagnostics, treatment and prevention, are essential to address OC challenges in LMICs [12,13]. ...

Variations In Level Of Surgery And Optimal Cytoreduction Amongst 2,446 Women With Ovarian Cancer In 22 Low- And Middle-Income Countries: The Every Woman Study Cohort
  • Citing Article
  • February 2025

International Journal of Gynecological Cancer

... Breast cancer (BC) is the most common type of cancer, commonly diagnosed in women, although it can occur in men [1]. It poses a significant health burden globally, with over 2 million new cases diagnosed in 2022 [2]. It is also one of the leading causes of death in women worldwide, despite its downward trend, particularly in developed countries. ...

Current and future burden of female breast cancer in the Middle East and North Africa region using estimates from GLOBOCAN 2022

... These factors contributed to increased psychological stress and anxiety among oncology patients. This has been confirmed by numerous systematic reviews and meta-analyses conducted by Riera et al. (2021), Tegelia, Angelini and Astolfi (2022), and Shah et al. (2025) [27,28,29]. Studies have also shown that changes in active cancer treatment and restrictions on social contact were associated with a deterioration in patients' mental well-being. ...

The global impact of the COVID-19 pandemic on delays and disruptions in cancer care services: a systematic review and meta-analysis

Nature Cancer

... Oropharyngeal squamous cell carcinoma (OPSCC) represents a significant global health burden, with an estimated annual incidence of 93,000 cases [1][2][3][4]. Around the year 2000, human papillomavirus (HPV) has been established as an etiological agent for OPSCC, with over 70% of cases in high-income regions such as North America and Europe now attributed to HPV infection [5][6][7]. However, epidemiologic data from China reveal a distinct landscape, with HPV-mediated OPSCC remaining comparatively rare, suggesting region-specific etiologic and environmental influences [8,9]. ...

The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide

... Accumulating evidence attributes the declining PCa incidence in HICs to reduced reliance on PSA screening, alongside the integration of multiparametric magnetic resonance imaging into diagnostic protocols. Such advancements enable more precise identification of clinically significant PCa, thereby curbing overdiagnosis and unnecessary biopsies (32,49). Moreover, studies highlight the association between lower PCa-related DALYs and mortality rates in high SDI regions with superior quality in healthcare delivery, including early detection programs, prevention interventions, and optimized therapeutic management (50). ...

Recent Patterns and Trends in Global Prostate Cancer Incidence and Mortality: An Update
  • Citing Article
  • December 2024

European Urology

... Kanker payudara merupakan salah satu jenis kanker yang paling umum pada wanita di seluruh dunia, termasuk di Indonesia. Menurut laporan WHO dalam Morgan et al. (2024), kanker payudara menyumbang lebih dari 2,3 juta kasus baru setiap tahun. Tingginya angka kejadian ini menuntut pendekatan terapi yang holistik, yang tidak hanya berfokus pada pengobatan medis tetapi juga mencakup faktor psikososial seperti dukungan keluarga. ...

Metastatic recurrence in women diagnosed with non-metastatic breast cancer: a systematic review and meta-analysis

Breast Cancer Research

... 8 For example, a 2024 systematic review and meta-analysis of all studies on alcohol use and female breast cancer showed that for consumption of less than one standard drink (10 g pure alcohol per day), the relative risk estimate for breast cancer was significantly elevated at 1·04 (95% CI 1·01-1·07) compared with the counterfactual scenario of not drinking. 9 Such information is important, together with absolute risk information, since many women consume alcohol at lower levels than men. 10 Consequently, relatively large proportions of alcohol-attributable cancer (14%) are caused by drinking fewer than two drinks a day globally; in absolute numbers, this amounts to more than 100 000 cases a year. 2 In the past two decades, alcohol producers have strongly opposed the introduction of mandatory cancer warning labels on alcohol beverage containers in various jurisdictions. 11 Such opposition has even resulted in the termination of research examining the use of cancer warning labels. ...

Alcoholic beverage consumption and female breast cancer risk: A systematic review and meta‐analysis of prospective cohort studies

... Additionally, this study looks at trends in leukemia cases, deaths, and the impact on quality of life, aiming to uncover inequalities and provide insights for designing better interventions. The findings of this study serve as an important extension and supplement to previous research on the leukemia burden (15,16) and also contribute to the development of leukemia response strategies tailored to different countries and regions. ...

Global patterns of leukemia by subtype, age, and sex in 185 countries in 2022

Leukemia